根据PARAGON-HF的多药性状态,萨库比特里尔/瓦尔萨坦的作用
Shingo Matsumoto1, Mingming Yang1, Li Shen1
1British Heart Foundation Cardiovascular Research Centre, University of Glasgow, Glasgow, UK.
European journal of heart failure
|April 8, 2024
概括
多种药物在心力衰竭中常见,其中包括保留喷射分数 (HFpEF) 患者,与更糟糕的结果相关. 萨库比特里尔/瓦尔沙坦在不同的药物使用水平上显示了持续的益处,包括那些具有多种药物的药物.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 保存喷射分数 (HFpEF) 的心力衰竭的特点是伴随性疾病的高患病率.
- 患有HFpEF的患者通常需要多种药物,导致多种药物.
- 了解多药对HFpEF治疗结果的影响至关重要.
研究的目的:
- 评估HFpEF患者的多药性状态和临床结果之间的关联.
- 在PARAGON-HF试验中,评估与瓦尔萨坦相比,萨库比特里尔/瓦尔萨坦在不同程度的多药性患者中的疗效.
主要方法:
- 一个对帕拉贡-HF试验的后期分析,涉及4793名患者.
- 根据基线药物使用情况,患者被分为非多药 (<5种药物),多药 (5-9种药物) 和超多药 (≥10种药物) 组.
- 评估的主要结果是整体心力衰竭住院和心血管死亡的复合结果.
主要成果:
- 超多药患者年龄较大,HF症状更严重,并具有更高的并发症负担.
- 在基线时增加的药物数量与首要结局的风险更高有关.
- 萨库比特里尔/瓦尔萨坦与瓦尔萨坦对主要结局的有益影响在多药类别中是一致的,超多药组的益处趋势更大 (比率比率0.77 [0.61-0.96]).
结论:
- 多药在HFpEF中非常普遍,并且与较差的临床状态和不良结果有关.
- 萨库比特里尔/瓦尔沙坦证明了有效性,无论基线药物的数量如何.
- 这些发现支持在HFpEF多药患者中使用萨库比特里尔/瓦尔萨坦.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:23Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
134
The elimination half-life and drug clearance of drugs following nonlinear kinetics can vary with dosage. The Michaelis-Menten parameters and drug concentration influence these factors. As the dose increases, the elimination half-life tends to lengthen, resulting in a reduction in clearance and a disproportionately larger area under the curve. The total clearance can be derived from the Michaelis-Menten equation for drugs following a one-compartment model.
A study on guinea pigs examined the...
A study on guinea pigs examined the...
134
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
720
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
720
01:28Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
150
Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
150
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K